Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Clinical Insights on Tildrakizumab 200 mg for Managing Complex Psoriasis: A Case Series Analysis

  • By

  • Giulia Odorici

  • Cinzia Buligan

  • Carolina Fantini

  • Lucia Mantovani

  • Giulia Rech

  • Lidia Sacchelli

  • July 14, 2026

Share

  • 1

    Tildrakizumab 200 mg showed high effectiveness in patients with moderate-to-severe psoriasis and multiple comorbidities.

  • 2

    Most patients achieved PASI90 or PASI100 responses within 4–12 weeks, with complete clearance in four out of six cases.

  • 3

    Treatment effectiveness was maintained over approximately 24 months, demonstrating a favorable safety profile.

  • 4

    The study highlights the challenges of managing psoriasis in patients with high disease burden and difficult-to-treat areas.

  • 5

    Real-world evidence supports the use of tildrakizumab for patients with prior therapeutic failures and complex clinical profiles.

Original Source(s)

Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series

  • by Giulia Odorici, Cinzia Buligan, Carolina Fantini, Lucia Mantovani, Giulia Rech, Lidia Sacchelli

  • July 14, 2026

Related Content

T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes

The therapeutic potential of natural products for pediatric psoriasis: targeting the immune microenvironment

Early Response to Calcipotriol and Betamethasone Dipropionate PAD-Cream at Week 4 in Patients with Mild-to-Moderate Plaque Psoriasis: A Post-Hoc Pooled Analysis of Two Phase III Trials